Every 10-Q that SYNLOGIC INC (SYBX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SYBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SYBX filings page.
Synlogic, Inc. reports minimal operating activity as a biopharma shell while pursuing a transformational merger with Caldera Therapeutics. For the six months ended June 30, 2026, revenue was $0, operating expenses were $2.3 million, and net income was $0.1 million, driven largely by a $2.2 million non‑cash gain from remeasuring warrant liabilities. Cash and cash equivalents were $13.2 million and total assets $13.5 million, against an accumulated deficit of $442.5 million; management believes current cash will fund operations for at least 12 months.
On July 28, 2026, Synlogic agreed to merge with Caldera under a new parent, with a concurrent $278.0 million Caldera financing. On a pro forma basis, legacy Synlogic holders are expected to own about 2.3% of the combined company, Caldera holders 62.8% and new investors 34.9%, subject to valuation and cash adjustments. The combined business will focus on Caldera’s CLD‑423 antibody for inflammatory bowel disease. Synlogic remains quoted on the OTC market after a Nasdaq delisting and continues to report a previously identified material weakness in internal control over financial reporting.
Synlogic, Inc. reported no revenue for the quarter ended March 31, 2026 but posted net income of $681,000, up from $317,000 a year earlier, mainly due to a non-cash $1.9 million gain from remeasuring purchase warrant liabilities.
Operating expenses were modest at $1.3 million, reflecting its status as a shell company following the 2024 shutdown of its lead PKU trial and broad restructuring to one full-time employee. Cash and cash equivalents totaled $14.1 million, and management believes this will fund operations for at least 12 months. The company’s shares were delisted from Nasdaq and now trade on the OTC marketplace, and a previously disclosed material weakness in internal controls remains unresolved as Synlogic actively pursues strategic alternatives, including a possible merger or sale.
Synlogic, Inc. (SYBX) filed its Q3 2025 report, highlighting a small operating footprint while pursuing strategic alternatives, including a possible merger or sale. The company recorded a net loss of $2.3 million for the quarter, driven largely by a $1.5 million loss from the change in fair value of purchase warrant liabilities.
Operating expenses were $1.0 million, reflecting minimal R&D activity after discontinuing the pivotal Synpheny‑3 trial in 2024 and completing a broad restructuring. Cash and cash equivalents were $15.6 million as of September 30, 2025, with management stating this is sufficient to fund operations for at least 12 months from the filing date. Stockholders’ equity stood at $10.3 million and purchase warrant liabilities at $5.3 million.
For the nine months, the company reported a net loss of $2.5 million, a significant improvement from the prior year due to restructuring completion and reduced operating costs. As of November 6, 2025, 11,698,919 shares were outstanding.